SCRI Unveils Groundbreaking Blood Cancer and Blood Disorder Research Through 100 Abstracts at 2025 ASH Annual Meeting In a historic showing that underscores its growing prominence in hematology research, the Sarah Cannon Research Institute (SCRI) will present 100 abstracts and…
AdvanCell Launches Pivotal Phase 2 Expansion Trial of ADVC001, a First-in-Class Targeted Alpha Therapy for Metastatic Prostate Cancer AdvanCell, a clinical-stage radiopharmaceutical company at the forefront of developing next-generation targeted alpha therapies (TATs) for oncology, has announced the initiation of…
Samsung Bioepis Launches Denosumab Biosimilars OBODENCE™ and XBRYK™ in Europe to Improve Access and Patient Outcomes Samsung Bioepis Co., Ltd., a global biopharmaceutical company recognized for its innovative work in developing biosimilars across multiple therapeutic areas, today announced the commercial…
Janux Therapeutics Reports Encouraging Interim Phase 1 Data for JANX007 in mCRPC, Highlighting Strong Efficacy and Manageable Safety Profile Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company pioneering novel immunotherapies through its proprietary platforms—Tumor Activated T Cell Engager (TRACTr), Tumor Activated…
AltPep Corporation Presents New Preclinical Data Demonstrating SOBIN-AD Peptide Improves Cognition in Early and Symptomatic Alzheimer’s Disease Models at CTAD 2025 AltPep Corporation, a privately held biotechnology company dedicated to developing early disease-modifying therapies and innovative detection tools for amyloid-related…
Vistagen Appoints Nick Tressler as Chief Financial Officer, Strengthening Leadership Team Amid Growth and Clinical Milestones Vistagen Therapeutics, Inc. a late clinical-stage biopharmaceutical company focused on pioneering neuroscience innovations through nose-to-brain neurocircuitry, today announced the appointment of Nick Tressler as…
Mirum Pharmaceuticals Enrolls First Participant in BLOOM Phase 2 Study Evaluating MRM-3379 for Fragile X Syndrome Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and delivering innovative therapies for rare diseases, announced today a key milestone in its development…
Circle Pharma Appoints Anne E. Borgman, M.D., as Chief Medical Officer, Strengthening Leadership Team to Advance Next-Generation Macrocycle Oncology Pipeline Circle Pharma, Inc., a clinical-stage biopharmaceutical company advancing a new class of targeted macrocycle therapeutics designed to address some of…
Celltrion Receives Health Canada Approval for Eydenzelt®, a Biosimilar Referencing Eylea® Celltrion, Inc. has announced a major regulatory milestone with the approval of Eydenzelt® by Health Canada. The newly approved biosimilar references Eylea® (aflibercept 2mg) and will be available to…
Otsuka Announces FDA Accelerated Approval of VOYXACT® for Proteinuria Reduction in Adults with Primary IgA Nephropathy Otsuka Pharmaceutical Development & Commercialization, Inc., together with Otsuka Pharmaceutical Co., Ltd., announced that the U.S. Food and Drug Administration (FDA) has granted accelerated…
Enigma Biomedical USA Awarded $2 Million Grant from The Michael J. Fox Foundation to Advance Novel α-Synuclein PET Imaging Biomarker for Parkinson’s Disease Enigma Biomedical USA (EB USA) today announced that The Michael J. Fox Foundation for Parkinson’s Research (MJFF)…
AstraZeneca Announces $2 Billion Expansion to Strengthen Maryland Manufacturing, Advance Innovation, and Support 2,600 Jobs AstraZeneca today unveiled a major strategic investment plan totaling $2 billion to expand its long-standing manufacturing presence in Maryland, further solidifying the state’s role as…